Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the
Por um escritor misterioso
Descrição

Nivolumab Combined with Ipilimumab

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma - Southern Iowa Mental Health Center

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
The New England Journal of Medicine - In patients with untreated metastatic melanoma, the addition of ipilimumab (anti-CTLA4) to nivolumab (anti-PD1) did not further improve response rate or progression-free survival in PD-L1

Considerations for First-Line Metastatic Melanoma: Which Treatment Is Best?

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study - European Journal of Cancer
de
por adulto (o preço varia de acordo com o tamanho do grupo)